

2019 Neurofibromatoses Type I Ongoing Clinical Trials Study- Companies, Countries, Drugs, Phases, Enrollment, Current Status and Markets

<https://marketpublishers.com/r/2B0916CA8CAEN.html>

Date: February 2019

Pages: 59

Price: US\$ 2,199.00 (Single User License)

ID: 2B0916CA8CAEN

Abstracts

The ongoing clinical trial research report- “2019 Neurofibromatoses Type I Ongoing Clinical Trials Study” analyzes the current scenario of all active Neurofibromatoses Type I trials across the world. The report presents top level analysis of global Neurofibromatoses Type I clinical trials across countries, companies and universities. It is designed to provide clear understanding into the Neurofibromatoses Type I trials landscape to assist users for effective long term strategy formulation to beat competition.

The report covers a key snapshot of ongoing trial count, average enrollment per trial across countries.

It also segments the Neurofibromatoses Type I clinical trials by-

Region (Asia Pacific, Europe, Middle East Africa and Americas)

Countries

Trial Phase

Current Trial Status (Recruiting, Active, Planned, Active but Completed Recruiting, Not Yet Recruiting etc)

Type of the trial (Interventional, Observational)

Sponsor Type (Companies, Universities, Government Bodies etc)

Enrollment across types, sponsor types, geographies, current status and phases

The report also identifies the potential drug candidates under development for treatment of Neurofibromatosis Type I on the basis of intervention type ongoing Neurofibromatosis Type I trials.

The research work is prepared through extensive and continuous research on Neurofibromatosis Type I trials from over 150 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

REPORT SCOPE AND COVERAGE:

All major ongoing trials from 2010 to 2019 and planned trials are included in the report scope.

Drug candidates currently being researched for administering Neurofibromatosis Type I patients are identified

The report includes panorama of ongoing Neurofibromatosis Type I clinical trials across the globe

Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided

Companies and universities focusing on Neurofibromatosis Type I clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)

Average Enrollment number, insights into enrollment trends, company wise enrollment are included

Both interventional and observational studies are analyzed

News and latest developments for the past one year are presented in the report

Contents

1. TABLE OF CONTENTS

1.1 List of Figures

1.2 List of Tables

2. EXECUTIVE SUMMARY

2.1 Neurofibromatoses Type I Ongoing Clinical Trials Overview, 2019

2.2 Premium Insights into Ongoing Clinical Trials

2.2.1 Ongoing Neurofibromatoses Type I Clinical Trials by Region

2.2.2 Average Enrollment of Neurofibromatoses Type I Clinical Trials

2.2.3 Companies participating in Ongoing Trials

2.2.4 Drugs under Study for Neurofibromatoses Type I Treatment, 2019

3. REGION WISE NEUROFIBROMATOSES TYPE I CLINICAL TRIALS

3.1 Asia Pacific Neurofibromatoses Type I Clinical Trials by Country

3.2 Europe Neurofibromatoses Type I Clinical Trials by Country

3.3 North America Neurofibromatoses Type I Clinical Trials by Country

3.4 Middle East and Africa Neurofibromatoses Type I Clinical Trials by Country

3.5 South and Central America Neurofibromatoses Type I Clinical Trials by Country

4. NEUROFIBROMATOSES TYPE I CLINICAL TRIAL TRENDS

4.1 Start Year wise Ongoing Neurofibromatoses Type I Clinical Trials

4.2 Phase wise Ongoing Neurofibromatoses Type I Clinical Trials

4.3 Trial Status wise Ongoing Neurofibromatoses Type I Clinical Trials

4.4 Trial Type wise Ongoing Neurofibromatoses Type I Clinical Trials

5. NEUROFIBROMATOSES TYPE I AVERAGE ENROLLMENT TRENDS

5.1 Average Enrollment in Neurofibromatoses Type I Trials by Year

5.2 Average Enrollment in Neurofibromatoses Type I Trials by Phase

5.3 Average Enrollment in Neurofibromatoses Type I Trials by Status

5.4 Average Enrollment in Neurofibromatoses Type I Trials by Type of Trial

6. COMPANIES PARTICIPATING IN ONGOING NEUROFIBROMATOSES TYPE I

CLINICAL TRIALS

- 6.1 Ongoing Neurofibromatoses Type I Trials by Sponsor Type
- 6.2 Neurofibromatoses Type I Average Enrollment by Sponsor Type
- 6.3 Subjects Recruited by Leading Sponsors

7 TRIAL SNAPSHOTS- PHASE, TYPE, TITLE, LOCATION, START YEAR, COMPLETION YEAR, RECRUITMENT STATUS, ENROLLMENT, PARTICIPATING COUNTRIES, TRIAL LOCATIONS, COMPANY, DRUGS AND OTHER DETAILS

- 7.1 Ongoing Neurofibromatoses Type I Trials- Phase
- 7.2 Ongoing Neurofibromatoses Type I Trials- Phase
- 7.3 Ongoing Neurofibromatoses Type I Trials- Phase
- 7.4 Ongoing Neurofibromatoses Type I Trials- Phase

8. APPENDIX

- 8.1 Report Guidance
- 8.2 Research Methodology
- 8.3 Abbreviations
- 8.4 Definitions
- 8.5 Sources
- 8.6 Publisher Expertise

List Of Figures

LIST OF FIGURES

- Figure 1: Neurofibromatoses Type I Ongoing Clinical Trials by Region, 2019
- Figure 2: Country wise Clinical Trials, 2019
- Figure 3: Country wise Average Enrolment, 2019
- Figure 4: Asia Pacific – Country wise Ongoing Neurofibromatoses Type I Clinical Trials and Enrolment
- Figure 5: Europe – Country wise Ongoing Neurofibromatoses Type I Clinical Trials and Enrolment
- Figure 6: Middle East Africa – Country wise Ongoing Neurofibromatoses Type I Clinical Trials and Enrolment
- Figure 7: North America – Country wise Ongoing Neurofibromatoses Type I Clinical Trials and Enrolment
- Figure 8: South and Central America – Country wise Ongoing Neurofibromatoses Type I Clinical Trials and Enrolment
- Figure 9: Neurofibromatoses Type I Ongoing Clinical Trials by Phase
- Figure 10: Neurofibromatoses Type I Ongoing Clinical Trials by Trial Status
- Figure 11: Neurofibromatoses Type I Ongoing Clinical Trials by Type
- Figure 12: Neurofibromatoses Type I Ongoing Clinical Trials by Sponsor Type
- Figure 13: Neurofibromatoses Type I Ongoing Clinical Trials by Leading Sponsors
- Figure 14: Neurofibromatoses Type I Average Enrollment by Phase
- Figure 15: Neurofibromatoses Type I Average Enrollment by Trial Status
- Figure 16: Neurofibromatoses Type I Average Enrollment by Type
- Figure 17: Neurofibromatoses Type I- Average Enrolment by Type of Sponsors
- Figure 18: Neurofibromatoses Type I- Enrolment by Leading Sponsors
- Figure 19: VPAResearch- Research Methodology

List Of Tables

LIST OF TABLES

Table 1: Neurofibromatoses Type I Ongoing Clinical Trials Snapshot- 2019

Table 2: Ongoing Trials by Region, 2019

Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019

Table 4: Asia Pacific – Country wise Ongoing Neurofibromatoses Type I Clinical Trials and Enrolment

Table 5: Europe – Country wise Ongoing Neurofibromatoses Type I Clinical Trials and Enrolment

Table 6: Middle East Africa – Country wise Ongoing Neurofibromatoses Type I Clinical Trials and Enrolment

Table 7: North America – Country wise Ongoing Neurofibromatoses Type I Clinical Trials and Enrolment

Table 8: South and Central America – Country wise Ongoing Neurofibromatoses Type I Clinical Trials and Enrolment

Table 9: Clinical Trials by Phase

Table 10: Clinical Trials by Trial Status

Table 11: Clinical Trials by Type

Table 12: Clinical Trials by Sponsor Type

Table 13: Clinical Trials by Leading Sponsors

Table 14: Neurofibromatoses Type I Average Enrollment by Phase

Table 15: Neurofibromatoses Type I Average Enrollment by Trial Status

Table 16: Neurofibromatoses Type I Average Enrollment by Type

Table 17: Neurofibromatoses Type I- Average Enrolment by Type of Sponsors

Table 18: Neurofibromatoses Type I- Enrolment by Leading Sponsors

I would like to order

Product name: 2019 Neurofibromatoses Type I Ongoing Clinical Trials Study- Companies, Countries, Drugs, Phases, Enrollment, Current Status and Markets

Product link: <https://marketpublishers.com/r/2B0916CA8CAEN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2B0916CA8CAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

